ArticleBMC cancer2019
Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Receptor binding domain-independent pancoronavirus vaccine design by fusion of conserved T/B Epitopes.Emerging microbes & infections · 2026Article
- Nanovesicles With Mechanically Induced Adjuvanticity for Robust Melanoma Vaccination Toward Tumor-Associated Macrophages.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses.NPJ vaccines · 2025Article
- Immune responses to human papillomavirus infection and vaccination.Frontiers in immunology · 2025Review
- Vaccination with synthetic long peptide and CpG 2395 in AddaVax induces potent anti-tumor effects.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Tumor Antigens beyond the Human Exome.International journal of molecular sciences · 2024Review
- Article
- Current status and future directions for the development of human papillomavirus vaccines.Frontiers in immunology · 2024Review
- Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.MedComm · 2023Review
- Enhanced HPV16 E6/E7Cancer immunology, immunotherapy : CII · 2023Article
- Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Liposomal delivery system/adjuvant for tuberculosis vaccine.Immunity, inflammation and disease · 2023Review
- Nanoparticle vaccines can be designed to induce pDC support of mDCs for increased antigen display.Biomaterials science · 2023Article
- Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4Journal for immunotherapy of cancer · 2022Review
- Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer.Cancers · 2022Review
- The association of cervicovaginal Langerhans cells with clearance of human papillomavirus.Frontiers in immunology · 2022Review
- Therapeutic cancer vaccines revamping: technology advancements and pitfalls.Annals of oncology : official journal of the European Society for Medical Oncology · 2021Review
- Multifaceted glycoadjuvant@AuNPs inhibits tumor metastasis through promoting T cell activation and remodeling tumor microenvironment.Journal of nanobiotechnology · 2021Article
- Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.Gastroenterology · 2021Article
- HPV-Associated Tumor Eradication by Vaccination with Synthetic Short Peptides and Particle-Forming Liposomes.Small (Weinheim an der Bergstrasse, Germany) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite considerable efforts at developing therapeutic vaccines for cancer, clinical translation of preclinical successes has been challenging, largely due to the difficulty of inducing strong and sustained cytotoxic T lymphocyte (CTL) responses in patients. Several peptide-based cancer vaccines have failed to show sustainable tumor regression in the clinic, possibly because of a lack of optimization of both the adjuvant and antigen components of the preparations. Here, we aimed to develop and optimize a vaccine format utilizing a synthetic long peptide (SLP) containing the human papilloma virus 16 (HPV16) E7 antigen, with a centrally located defined MHC class I epitope, and evaluate its immunogenicity and efficacy in combination with various adjuvant formulations.
methodsE7
resultsWe identified the TLR9 agonist CpG formulated in a squalene-based o/w emulsion as the most potent adjuvant, inducing the expansion of multifunctional antigen specific CD8 T cells with cytolytic potential. We also demonstrated that SLP E7
conclusionsOur results demonstrate that the novel vaccine format E7 SLP + CpG delivered in an o/w emulsion holds potential for the promotion of strong CTL responses and tumor eradication and encourages further development of peptide/adjuvant vaccines in cancer immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.